|
<!-- Legal data -->|legal_AU=S4|legal_CA=Rx-only|legal_UK=POM|legal_US=Rx-only|legal_status=Rx-only|DailyMedID=Celecoxib|licence_US=Celebrex|licence_EU=<!-- EMA uses INN (or special INN_EMA) -->
<!-- Pharmacokinetic data -->|bioavailability=Unknown<ref name=drugs>{{cite journal | vauthors = McCormack PL | title = Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis | journal = Drugs | volume = 71 | issue = 18 | pages = 2457–89 | date = December 2011 | pmid = 22141388 | doi = 10.2165/11208240-000000000-00000 }}</ref>|protein_bound=97% (mainly to [[serum albumin]])<ref name=drugs>{{cite journal | vauthors = McCormack PL | title = Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis | journal = Drugs | volume = 71 | issue = 18 | pages = 2457–89 | date = December 2011 | pmid = 22141388 | doi = 10.2165/11208240-000000000-00000 }}</ref>|metabolism=Liver (mainly [[CYP2C9]])<ref name=drugs>{{cite journal | vauthors = McCormack PL | title = Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis | journal = Drugs | volume = 71 | issue = 18 | pages = 2457–89 | date = December 2011 | pmid = 22141388 | doi = 10.2165/11208240-000000000-00000 }}</ref>|metabolites=|elimination_half-life=7.8 hours; 11 hours (mild hepatic impairment); 13 hours (moderate-severe hepatic impairment)<ref name=drugs>{{cite journal | vauthors = McCormack PL | title = Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis | journal = Drugs | volume = 71 | issue = 18 | pages = 2457–89 | date = December 2011 | pmid = 22141388 | doi = 10.2165/11208240-000000000-00000 }}</ref>|excretion=Faeces (57%), urine (27%)<ref name=drugs>{{cite journal | vauthors = McCormack PL | title = Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis | journal = Drugs | volume = 71 | issue = 18 | pages = 2457–89 | date = December 2011 | pmid = 22141388 | doi = 10.2165/11208240-000000000-00000 }}</ref>
<!-- Chemical and physical data -->|C=17|F=3|H=14|N=3|O=2|S=1|smiles=O=S(=O)(c3ccc(n1nc(cc1c2ccc(cc2)C)C(F)(F)F)cc3)N|StdInChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)|StdInChI_Ref={{stdinchicite|correct|chemspider}}|StdInChI_comment=|StdInChIKey=RZEKVGVHFLEQIL-UHFFFAOYSA-N|StdInChIKey_Ref={{stdinchicite|correct|chemspider}}|molecular_weight=381.373|density=|melting_point=|melting_high=|melting_notes=|boiling_point=|boiling_notes=|solubility=|specific_rotation=}}
'''Celecoxib''' adalah obat penghambat COX-2 dan [[Obat antiinflamasi nonsteroid|obat anti inflamasi nonsteroid]] (NSAID). <ref name="AHFS2019">{{Cite web|title=Celecoxib Monograph for Professionals |url=https://www.drugs.com/monograph/celecoxib.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists |date=11 November 2019 |archive-date=20 May 2019 |archive-url=https://web.archive.org/web/20190520124313/https://www.drugs.com/monograph/celecoxib.html |url-status=live |access-date=5 May 2020}}</ref> Obat ini dipergunakan untuk mengatasi [[nyeri]] dan [[Radang|peradangan]] pada [[Osteoartritis|osteoarthritis]], [[Nyeri|nyeri akut]] pada orang dewasa, [[Rheumatoid Arthritis|rheumatoid arthritis]], [[ankilosing spodilitis]], dan [[dismenorea]]. <ref name="AHFS2019">{{cite web |title=Celecoxib Monograph for Professionals |url=https://www.drugs.com/monograph/celecoxib.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists |date=11 November 2019 |accessdate=5 May 2020 |archive-date=20 May 2019 |archive-url=https://web.archive.org/web/20190520124313/https://www.drugs.com/monograph/celecoxib.html |url-status=live }}</ref> Obat ini juga bisa dipergunakan untuk mengurangi risiko adenoma kolorektal pada penderita dengan poliposis adenomatosa familial . <ref name="AHFS2019">{{cite web |title=Celecoxib Monograph for Professionals |url=https://www.drugs.com/monograph/celecoxib.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists |date=11 November 2019 |accessdate=5 May 2020 |archive-date=20 May 2019 |archive-url=https://web.archive.org/web/20190520124313/https://www.drugs.com/monograph/celecoxib.html |url-status=live }}</ref> Rute pemberian obat melalui oral . <ref name="AHFS2019">{{cite web |title=Celecoxib Monograph for Professionals |url=https://www.drugs.com/monograph/celecoxib.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists |date=11 November 2019 |accessdate=5 May 2020 |archive-date=20 May 2019 |archive-url=https://web.archive.org/web/20190520124313/https://www.drugs.com/monograph/celecoxib.html |url-status=live }}</ref> Efek terapi akan terlihat dalam waktu 1jam. <ref name="AHFS2019">{{cite web |title=Celecoxib Monograph for Professionals |url=https://www.drugs.com/monograph/celecoxib.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists |date=11 November 2019 |accessdate=5 May 2020 |archive-date=20 May 2019 |archive-url=https://web.archive.org/web/20190520124313/https://www.drugs.com/monograph/celecoxib.html |url-status=live }}</ref>
Kejadian efek samping yang umum bisa terjadi seperti [[mulas]], mual, dan [[diare]] . <ref name="AHFS2019">{{Cite web|title=Celecoxib Monograph for Professionals |url=https://www.drugs.com/monograph/celecoxib.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists |date=11 November 2019 |archive-date=20 May 2019 |archive-url=https://web.archive.org/web/20190520124313/https://www.drugs.com/monograph/celecoxib.html |url-status=live |access-date=5 May 2020}}<cite class="citation web cs1" data-ve-ignore="true">[https://www.drugs.com/monograph/celecoxib.html "Celecoxib Monograph for Professionals"]. ''Drugs.com''. American Society of Health-System Pharmacists. 11 November 2019. [https://web.archive.org/web/20190520124313/https://www.drugs.com/monograph/celecoxib.html Archived] from the original on 20 May 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">5 May</span> 2020</span>.</cite></ref> Efek samping serius yang bisa terjadi yakni [[serangan jantung]], [[Strok|stroke]], perforasi saluran cerna, [[Pendarahan gastrointestinal|perdarahan gastrointestinal]], gagal ginjal, dan [[anafilaksis]] . <ref name="Coxib2013">{{Cite journal|date=August 2013|title=Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials|journal=Lancet|volume=382|issue=9894|pages=769–79|doi=10.1016/S0140-6736(13)60900-9|pmc=3778977|pmid=23726390|vauthors=Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C}}</ref> <ref name="AHFS2019">{{cite web |title=Celecoxib Monograph for Professionals |url=https://www.drugs.com/monograph/celecoxib.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists |date=11 November 2019 |accessdate=5 May 2020 |archive-date=20 May 2019 |archive-url=https://web.archive.org/web/20190520124313/https://www.drugs.com/monograph/celecoxib.html |url-status=live }}</ref> Obat ini tidak direkomendasikan untuk individu yang memiliki risiko tinggi terkena penyakit jantung. <ref name="AHA2007">{{Cite journal|date=March 2007|title=Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association|journal=Circulation|volume=115|issue=12|pages=1634–42|doi=10.1161/circulationaha.106.181424|pmid=17325246|vauthors=Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA}}</ref> <ref name="Consumer2012">{{Cite web|date=August 2009|title=Should you still take Celebrex?|url=http://www.consumerreports.org/cro/2012/05/should-you-still-take-celebrex/index.htm|website=[[Consumer Reports]]|archive-url=https://web.archive.org/web/20151218111927/http://www.consumerreports.org/cro/2012/05/should-you-still-take-celebrex/index.htm|archive-date=18 December 2015|access-date=27 December 2015|url-status=live}}</ref> Risikonya obat ini sama dengan golongan NSAID lain, seperti [[ibuprofen]] dan [[Naproksen|naproxen]] . <ref name="NPR2018">{{Cite news|last=Stein|first=Rob|date=25 April 2018|title=FDA Panel Affirms Safety Of Painkiller Celebrex|url=https://www.npr.org/sections/health-shots/2018/04/25/605226604/fda-panel-affirms-safety-of-painkiller-celebrex|publisher=[[NPR]]|archive-url=https://web.archive.org/web/20180520123906/https://www.npr.org/sections/health-shots/2018/04/25/605226604/fda-panel-affirms-safety-of-painkiller-celebrex|archive-date=20 May 2018|access-date=19 May 2018|url-status=live}}</ref> Untuk pengguna ibu [[Kehamilan|hamil]] atau ibu [[menyusui]] tidak direkomendasikan untuk digunakan. <ref name="AHFS2019">{{cite web |title=Celecoxib Monograph for Professionals |url=https://www.drugs.com/monograph/celecoxib.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists |date=11 November 2019 |accessdate=5 May 2020 |archive-date=20 May 2019 |archive-url=https://web.archive.org/web/20190520124313/https://www.drugs.com/monograph/celecoxib.html |url-status=live }}</ref> <ref name="Drugs.com pregnancy">{{Cite web| title=Celecoxib (Celebrex) Use During Pregnancy | website=Drugs.com | date=4 May 2020 | url=https://www.drugs.com/pregnancy/celecoxib.html | access-date=5 May 2020 | archive-date=25 January 2021 | archive-url=https://web.archive.org/web/20210125072333/https://www.drugs.com/pregnancy/celecoxib.html | url-status=live }}</ref>
== Referensi ==
|
